XML 83 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting
 9 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Segment Reporting

The Company’s chief operating decision maker (the “CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

 

Aytu manages our Company and aggregated our operational and financial information in accordance with two reportable segments: Aytu BioScience and Aytu Consumer Health. The Aytu BioScience segment consists of the Company’s prescription products. The Aytu Consumer Health segment contains the Company’s consumers healthcare products line, which was the result of the Innovus Merger. Select financial information for these segments is as follows:

 

     Three months Ended March 31,      Nine months Ended March 31,  
    2020     2019     2020     2019  
 Consolidated revenue:                        
Aytu BioScience   $ 4,703,000     $ 2,378,000     $ 9,318,000     $ 5,605,000  
Aytu Consumer Health     3,453,000               3,453,000          
Consolidated revenue     8,156,000       2,378,000       12,771,000       5,605,000  
                                 
                                 
Consolidated net loss:                                
Aytu BioScience     (4,421,000 )     (4,496,000 )     (9,565,000 )     (12,600,000 )
Aytu Consumer Health     (911,000 )             (911,000 )        
Consolidated net loss     (5,332,000 )     (4,496,000 )     (10,476,000 )     (12,600,000 )

 

     March 31, 2020      June 30, 2019  
Total assets:                
Aytu BioScience   $  137,825,000     $  34,721,000  
Aytu Consumer Health     21,129,000        -  
Total assets   $ 158,954,000     $ 34,721,000